Citi raised the firm’s price target on Olema Oncology (OLMA) to $62 from $60 and keeps a Buy rating on the shares. The firm sees a favorable risk/reward into the company’s upcoming data following the stock’s re-rating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals: Palazestrant Phase III Upside and Differentiated Pipeline Underpin Buy Rating
- Buy Rating Reaffirmed on Palazestrant’s Differentiated Phase 3 Program and Favorable Risk‑Reward Profile for Olema
- Olema Oncology reports Q4 EPS (50c), consensus (53c)
- Maintaining a Buy on Olema: Differentiated Palazestrant Profile Supports Upside Despite Negative Giredestrant Read-Through
- Constructive Read‑Through From Giredestrant Data Supports Olema’s Palazestrant and Underpins Buy Rating Despite Sector Setbacks